Alemtuzumab Induction in Kidney Transplantation: Clinical Results and Impact on T-Regulatory Cells

J. Morales, M. R. Bono, A. Fierro, R. Iñiguez, C. Zehnder, M. Rosemblatt, L. Calabran, C. Herzog, D. Benavente, J. Aguiló, J. Pefaur, A. Alba, M. Ferrario, W. Simon, L. Contreras, E. Buckel

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Alemtuzumab (ALT), a humanized monoclonal anti-CD52 antibody, was introduced in solid organ transplantation as an induction agent. ALT associated with anticalcineurins has provided a low incidence of acute rejection episodes (ARE) and potential tolerogenic properties. We analyzed the clinical outcomes and effects on peripheral Treg of renal transplant recipients treated with ALT. Six-month data on kidney alone or kidney combined with pancreas or liver patients treated with ALT and tacrolimus (TAC) in standard doses were compared with those on renal transplant recipients of similar demography who were not treated with ALT. We evaluated patient and graft survivals, ARE incidence, hematological parameters, renal function, adverse events, and CD4+CD25+FoxP3+ T cells in peripheral blood. Demographics of recipients, donors, and transplants were similar in both groups. Mean HLA mismatch was slightly greater among ALT-treated patients (3.5 vs 2.5). No combined transplantation was performed in the ALT-untreated group. Patient and graft survivals were 100% without rejection or serious infections in both groups. ALT-treated recipients showed anemia and leukopenia in 3 patients as well as severe lymphopenia in 5 recipients, who partially recovered on day 90. Final mean plasma creatinine was 1.4 mg/dL, while calculated creatinine clearance was approximately 65 mL/min in both groups. Mean Treg cell percentage was higher among ALT-treated recipients than the comparative group or healthy controls (P < .05). In conclusion, renal transplantation results obtained using ALT with rigorous immunosuppressive therapy were excellent; serious adverse events and acute rejection were absent. The effect of the increased proportion of Treg cells must be evaluated with longer observation.

Original languageEnglish
Pages (from-to)3223-3228
Number of pages6
JournalTransplantation Proceedings
Issue number9
Publication statusPublished - Nov 2008

ASJC Scopus subject areas

  • Surgery
  • Transplantation


Dive into the research topics of 'Alemtuzumab Induction in Kidney Transplantation: Clinical Results and Impact on T-Regulatory Cells'. Together they form a unique fingerprint.

Cite this